Compare TNXP & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNXP | RPID |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.7M | 204.3M |
| IPO Year | 2008 | 2021 |
| Metric | TNXP | RPID |
|---|---|---|
| Price | $13.65 | $2.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 419.1K | 283.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.75 | 2.78 |
| EPS | N/A | ★ N/A |
| Revenue | $13,107,000.00 | ★ $33,587,000.00 |
| Revenue This Year | $558.11 | $19.12 |
| Revenue Next Year | $38.29 | $18.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 29.85 | 19.74 |
| 52 Week Low | $11.60 | $1.86 |
| 52 Week High | $69.65 | $4.94 |
| Indicator | TNXP | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 31.83 |
| Support Level | $13.32 | N/A |
| Resistance Level | $20.36 | $4.48 |
| Average True Range (ATR) | 1.18 | 0.20 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 37.93 | 19.00 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.